Contributed Poster Presentations Session I

ARTHRITIS


PAR1	GLUCOSAMINE VS PLACEBO IN THE TREATMENT OF OSTEOARTHRITIS: META-ANALYSIS
	O'Leary BA1, Glase KM1, Adena M2, Hutchinson RS2
	1Covance Pty Ltd, Sydney, NSW, Australia, 2Covance Pty Ltd, Canberra, ACT, Australia

PAR2	DOES RACE INFLUENCE A PATIENT'S LIKELIHOOD OF BEING PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS (COX-2S) VERSUS OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID MANAGED CARE PLANS (MCOS)?
	Neild A1, Cuffel B2
	1PPSI, Stamford, CT, USA, 2Harvard U, Boston, MA, USA

PAR3	COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS IN ARGENTINA
	Solé JP1, Ortega GP1, Kielhorn A2
	1Productos Roche S.A.Q.e I, Buenos Aires, Argentina, 2F. Hoffmann-La Roche AG, Basel, Switzerland

PAR4	ASSOCIATION BETWEEN SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) AND HEALTH CARE COSTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
	Tang B1, Rahman MI1, Meissner B2, Dabbous O1, Thompson HC1
	1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PAR5	ADALIMUMAB, ETANERCEPT OR INFLIXIMAB: WHAT IS THE MOST COST-EFFECTIVE ANTI-TNF-á THERAPY IN RA IN A REAL-WORLD SETTING?
	Deeg M1, Ekelund M2, Runge C1
	1Wyeth Pharma GmbH, Münster, Germany, 2Wyeth AB, Solna, Sweden

PAR6	A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL NERVE BLOCKADE TECHNIQUE
	Aguiar García F1, García Ruiz A2, Herrera Espiñeira C3, Bertrand García M1, Fernández Gordillo F1, Guerado Parra E1
	1Costa del Sol Hospital, Marbella, Málaga, Spain, 2Málaga University, Málaga, Málaga, Spain, 3Hospital Virgen de las Nieves, Granada, Granada, Spain

PAR7	COST EFFECTIVENESS OF AUTOANTIBODIES AGAINST CYCLIC CITRULLINATED PEPTIDE IN THE VERY EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS
	Konnopka A1, Conrad K2, Koenig HH1
	1University of Leipzig, Leipzig, Germany, 2Technical University Dresden, Dresden, Germany

PAR8	LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND: A COST-EFFECTIVENESS ANALYSIS
	Golicki D1, Niewada M1, Lis J2, Kaminski B3, Jakubczyk M1, Macioch T4
	1Medical University of Warsaw, Warsaw, Poland, 2Sanofi-Aventis, Warsaw, Poland, 3Warsaw School of Economics, Warszawa, Poland, 4Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PAR9	A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS
	Richard L1, Brown M2
	1UCB Celltech, Slough, UK, 2UCB, Slough, UK

PAR10	COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF ANTI-TNF-A DRUGS IN PSORIATIC ARTHRITIS
	Eandi M1, Zaniolo O2, Iannazzo S2, Pradelli L2
	1Università di Torino, Turin, Italy, 2Advanced Research Srl, Turin, Italy

PAR11	COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND
	Golicki D1, Niewada M2, Lis J3, Macioch T1
	1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2Medical University of Warsaw, Warsaw, Poland, 3Sanofi-Aventis, Polska, Warsaw, Poland

PAR12	FINANCIAL CONSEQUENCES OF THERAPEUTIC STRATEGIES IN OSTEOARTHRITIS TREATMENT IN CZECH REPUBLIC
	Skoupá J1, Cerna V1, Doležal T2, Cernek M3
	1Pharma Projects, Prague, Czech Republic, 23-rd Medical Faculty Charles University, Prague, Czech Republic, 3Zentiva a.s, Prague, Czech Republic

PAR13	ANNUAL TREATMENT COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH METOTREXATE AND LEFLUNOMIDE IN SPAIN
	Rebollo P1, Prieto L2, Garcia Ruiz A3, Betegon L4, Echevarria A5
	1BAP Health Outcomes, Oviedo, Asturias, Spain, 2Health Outcomes and Economics Consultant, Madrid, Madrid, Spain, 3Universidad de Málaga, Malaga, Malaga, Spain, 4IMS HEOR, Madrid, madrid, Spain, 5sanofi-aventis, Madrid, madrid, Spain

PAR14	COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Santos EA, Nasciben V
	Roche Brazil, Sao Paulo, SP, Brazil

PAR15	IMPACT OF CO-MORBIDITY BURDEN ON REAL WORLD HEALTHCARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS INITIATING ANTI-TUMOR NECROSIS FACTOR THERAPY
	Tang B1, Rahman MI1, Stephenson JJ2, Quimbo R2, Naim A1, Thompson HC1, Dabbous O1
	1Centocor, Inc, Horsham, PA, USA, 2HealthCore, Inc, Wilmington, DE, USA

PAR16	COST OF ANKYLOSING SPONDYLITIS IN CZECH REPUBLIC – DIRECT AND INDIRECT COSTS
	Dolezal T1, Skoupá J2, Cerna V2
	1Charles University, Prague, Czech Republic, 2Pharma Projects, Prague, Czech Republic

PAR17	A SYSTEMATIC REVIEW OF THE GLOBAL COST-OF-ILLNESS OF RHEUMATOID ARTHRITIS
	Richard L1, Brown M2
	1UCB Celltech, Slough, UK, 2UCB, Slough, UK

PAR18	HIDDEN COST OF RHEUMATOID ARTHRITIS: ESTIMATING COST OF COMORBID CARDIOVASCULAR DISEASE AND DEPRESSION AMONG RHEUMATOID ARTHRITIS PATIENTS
	Joyce AT1, Khandker RK2, Smith PJ1, Singh A2
	1PharMetrics, a unit of IMS, Watertown, MA, USA, 2Wyeth Research, Collegeville, PA, USA

PAR19	COMPARISON OF ORAL LEFLUNOMIDE AND METOTREXATE SC FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: AN APPROACH BASED ON THE NUMBER TO TREAT
	Garcia Ruiz A1, Betegon L2, Echevarria A3
	1Universidad de Málaga, Malaga, Spain, 2IMS HEOR, Madrid, Spain, 3sanofi-aventis, Madrid, Spain

PAR20	ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS WHO RECEIVED INFLIXIMAB THERAPY
	Nair KV1, Tang B2, Van Den Bos J3, Zhang V3, Naim A2, Rahman MI2
	1University of Colorado at Denver and the Health Sciences Center, Denver, CO, USA, 2Centocor, Inc, Horsham, PA, USA, 3Milliman, Inc, Denver, CO, USA

PAR21	IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
	Tang B1, Rahman MI1, Stephenson JJ2, Quimbo R2, Thompson HC1, Dabbous O1
	1Centocor, Inc, Horsham, PA, USA, 2HealthCore, Inc, Wilmington, DE, USA

PAR22	COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UK
	Lewis G1, Kielhorn A2, Diamantopoulos A3
	1Roche Products Limited, Welwyn Garden City, Herts, UK, 2F. Hoffmann-La Roche AG, Basel, Switzerland, 3IMS Health, London, UK

PAR23	COST-UTILITY OF ABATACEPT, A NEW BIOLOGIC TREATMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED ANTI-TNF THERAPY
	Hawkins NS1, Minda K2, Parry D2, Hines P3, Yuan Y4, Maclean R5
	1Oxford Outcomes (UK), Oxford, UK, 2Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, 3Bristol-Myers Squibb Pharmaceuticals, Plainsboro, NJ, USA, 4Bristol Myers Squibb, Princeton, NJ, USA, 5Bristol-Myers Squibb Pharmaceuticals, Lawrenceville, NJ, USA

PAR24	COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFA THERAPY IN HUNGARY
	Brodszky V1, Péntek M2, Karpati K1, Boncz I3, Sebestyén A4, Gulacsi L1
	1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3University of Pécs, Pécs, Hungary, 4National Health Insurance Fund Administration, Budapest, Hungary

PAR25	ASSOCIATION OF PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPY AND HEALTHCARE COSTS IN PATIENTS WITH PSORIATIC ARTHRITIS
	Tang B1, Rahman MI1, Meissner B2, Dabbous O1, Naim A1, Thompson HC1
	1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PAR26	THE UNINTENDED CONSEQUENCES OF WITHDRAWING DRUGS FROM THE MARKET
	Gilmore A
	Health Benchmarks, Inc, Woodland Hills, CA, USA

PAR27	WITHDRAWAL OF ROFECOXIB FROM THE MARKET; THERAPEUTIC AND ECONOMIC IMPLICATION FOR THE NETHERLANDS
	Boersma C, Pechlivanoglou P, Van den Berg PB, Shakele SN, Postma M
	University of Groningen, Groningen, The Netherlands

PAR28	GEOGRAPHICAL VARIATION OF PHARMACOLOGICAL PRESCRIPTION WITH BAYESIAN HIERARCHICAL MODELS
	López-Quílez A, Armero C, Forte A
	Universitat de València, Burjassot, Valencia, Spain

PAR29	AZATHIOPURINE, TPMT POLYMORPHISMS AND ADRS: THE COST OF NEUTROPENIA
	Compagni A1, Bartoli S1, Gutierrez de Mesa E2, Ibarreta D3
	1University of Bocconi, Milan, Italy, 2European Commission, DG-JRC, Seville, Spain, 3Institute for Prospective Technological Studies, JRC-European Commission, Seville, Spain

PAR30	SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
	Tang B1, Rahman MI1, Meissner B2, Naim A1, Thompson HC1, Dabbous O1
	1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PAR31	MULTILEVEL ANALYSIS: A NOVEL APPROACH FOR STATISTICAL ANALYSIS OF LONGITUDINAL STUDIES IN ORTHOPAEDICS
	Aulakh TS, Robinson EV, Kuiper JH, Richardson JB
	RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK

PAR32	INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOING TOTAL KNEE REPLACEMENT
	Zhang XH1, Li SC2, Xie F1, Lo NN3, Yang KY3, Yeo SJ3, Thumboo J3
	1National University of Singapore, Singapore, Singapore, 2University of Newcastle, Callaghan, NSW, Australia, 3Singapore General Hospital, Singapore, Singapore

PAR33	OSWESTRY HIP SCORE: A PATIENT ASSESSED TOOL TO MEASURE HIP FUNCTION
	Aulakh TS, Robinson EV, Richardson JB
	RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK

DIABETES


PDB1	GLYCEMIC CONTROL GOAL ATTAINMENT AMONG TYPE 2 DIABETIC PATIENTS WHO INITIATED ORAL COMBINATION THERAPY IN HUNGARY
	György B1, Hungarian RG2, Nagy L3, Erdesz D3, Yin D4, Krishnarajah G4
	1Bajcsy-Zsilinszly Hospital, MaglódiMaglódi, Hungary, 2Hungarian RECAP Group, NA, Hungary, 3MSD Hungary, Budapest, Hungary, 4Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB2	A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) PATIENTS WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) AND THIAZOLIDINEDIONES (TZD) AS ADD-ON THERAPY
	Fon F1, Celaya JM2, Ayala C3, Antunez O4, Garcia-Contreras F5
	1Novartis, Mexico City, Mexico, 2Novartis, Mexico DF, Mexico, 3Epieconomics Research, Mexico, DF, Mexico, 4Novartis, Mexico, DF, Mexico, 5Mexican Institute of Social Security, México, Distrito Federal, Mexico

PDB3	COMPARING EFFICIENCY OF INSULIN GLARGINE VS. NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES
	Kodela B1, Petrovic J2, Velickovic-Radovanovic R2, Lilic R2, Radenkovic S2, Dedovic I3
	1Pharmaceutical Institution, Nis, Serbia and Montenegro, 2Clinical Centre, Nis, Serbia and Montenegro, 3Faculty of Farmacy, Nis, Serbia and Montenegro

PDB4	A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) AND THIAZOLIDINEDIONES (TZD) IN MONOTHERAPY
	Celaya JM1, Fon F1, Ayala C2, Antunez O3, Garcia-Contreras F4
	1Novartis, Mexico City, Mexico, 2Epieconomics Research, Mexico City, DF, Mexico, 3Novartis, Mexico, DF, Mexico, 4Mexican Institute of Social Security, México, Distrito Federal, Mexico

PDB5	GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS
	Wintle M1, Guan X1, Brodows R2, Mac S1
	1Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB6	DATABASE ASSESSMENT OF THE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
	Katzir I, Loebstein R, Vasterman landes J, Halkin H, Lomnicky Y
	Maccabi Healthcare Services, Tel Aviv, Israel

PDB7	ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL
	Littlewood K1, Whiteley J2, Mathieu C3
	1Mapi Values, Houten, The Netherlands, 2Pfizer Inc, New York, NY, USA, 3Katholieke Universiteit Leuven, Leuven, Belgium

PDB8	EVALUATION OF THE ASSOCIATION BETWEEN GLUCOSE VARIABILITY, AS MEASURED BY THE DIFFERENCE BETWEEN MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD GLUCOSE OBSERVATIONS, AND LONG TERM CLINICAL OUTCOME IN SUBJECTS WITH TYPE 2 DIABETES TREATED WITH INSULIN
	Poole C1, Tynan A2, Currie CJ3
	1Pharmatelligence Limited, Cardiff, UK, 2Eli Lilly and Company Limited, Surrey, UK, 3Cardiff University, Cardiff, UK

PDB9	INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR AND GLARGINE IN REDUCING WEIGHT GAIN AND ACHIEVING GLYCEMIC CONTROL, WHEN ADMINISTERED IN ADDITION TO CONVENTIONAL ORAL ANTIDIABETIC THERAPY IN THE TREATMENT OF TYPE 2 DIABETES PATIENTS; A META-ANALYSIS
	Fakhoury W1, Lockhart I1, Kotchie R1, Le Reun C2, Aagren M3, Nielsen S3
	1IMS Health, London, UK, 2IMS Health, Sydney, NSW, Australia, 3Novo Nordisk A/S, Bagsværd, Denmark

PDB10	UNDERSTANDING INSULIN THERAPY INITIATION FROM A PRIMARY CARE PERSPECTIVE IN THE UK USING LOCAL DATA
	McKendrick J1, Mavin K2, Parker J1, Kilcoyne A1, Watkins J1
	1Eli Lilly and Company Limited, Basingstoke, UK, 2Refer2us Management Consultants, Milton Keynes, UK

PDB11	ASSOCIATION BETWEEN TOPICAL CORTICOSTEROID USE AND DIABETES ONSET
	Van der Linden MW1, Schalk BW1, Penning-van Beest FJA2, Thomas VS3, Glendenning A4, Herings RMC2
	1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2PHARMO Institute, Utrecht, The Netherlands, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharma, Horsham, West Sussex, UK

PDB12	ROSIGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES: IMPLEMENTATION OF BUDGET IMPACT ANALYSIS SOFTWARE
	Zaniolo O1, Iannazzo S1, Bamfi F2
	1Advanced Research Srl, Turin, Italy, 2GlaxoSmithKline Spa, Verona, Veneto, Italy

PDB13	THE COST OF THE INEFFICIENCY IN DIABETES IN HEALTH PRIMARY CARE
	Garcia AJ1, Avila L2, Morata F2, García C3, Montesinos A4, Leiva F5
	1Universidad de Malaga. Facultad de Medicina, Málaga, Spain, 2CS Axarquía Oeste, Malaga, Spain, 3CS Velez Norte, Malaga, Spain, 4Hospital Regional Carlos Haya, Malaga, Spain, 5SERVICIO ANDALUZ DE SALUD, MALAGA, Spain

PDB14	2-YEAR GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS NPH INSULIN IN INDIVIDUALS WITH TYPE 2 DIABETES (T2DM)
	Leahy J1, Dain MP2, Rhoads GG3, Kennedy L4
	1University of Vermont College of Medicine, Burlington, VT, USA, 2sanofi-aventis, Paris, France, 3University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA, 4University of Florida, Gainesville, FL, USA

PDB15	LOWER RATE OF HOSPITALIZATION IN SUBSEQUENT YEAR OF INSULIN GLARGINE VS NPH INITIATION IN INDIVIDUALS WITH TYPE 2 DIABETES (T2DM)
	Leahy J1, Rhoads GG2, Wei W3
	1University of Vermont College of Medicine, Burlington, VT, USA, 2University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA, 3sanofi-aventis, U.S. Group, Bridgewater, NJ, USA

PDB16	GLYCEMIC CONTROL WITH INSULIN GLARGINE PLUS GLULISINE VERSUS PREMIX IN REAL WORLD PRACTICES -- A RANDOMIZED, PROSPECTIVE, OBSERVATIONAL STUDY
	Levin P1, Zhang Q2, Mersey J1, Lee F1, Bromberger L1, Bhushan M3, Jhaveri M4, Bhushan R3
	1Model Clinical Research, Baltimore, MD, USA, 2sanofi-aventis, Bridgewater, NJ, USA, 3Metabolic Center Of Louisiana Research Foundation, Baton Rouge, LA, USA, 4Rutgers University, Piscataway, NJ, USA

PDB17	MEDICAL COSTS AMONG INDIVIDUALS WITH DIABETES, HYPERTENSION OR HYPERCHOLESTEROLEMIA
	Lage MJ1, Boye KS2
	1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB18	THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE: AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTO THE FUTURE USING A VALID AND RELIABLE ECONOMIC MODEL FROM A THIRD PARTY PAYER PERSPECTIVE IN THE USA
	Minshall M1, St. Charles M1, Pandya B2, Baran RW2
	1IMS Health, Noblesville, IN, USA, 2Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

PDB19	THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH SITAGLIPTIN: AN ECONOMIC EVALUATION USING A VALIDATED ECONOMIC MODEL FROM A THIRD PARTY PAYER PERSPECTIVE IN THE USA
	Minshall M1, St. Charles M1, Pandya B2, Baran RW2, Bron M2
	1IMS Health, Noblesville, IN, USA, 2Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

PDB20	COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS
	Aristides M1, Kotchie R1, Nielsen S2, Aagren M2, Valentine WJ3, Goodall G3
	1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

PDB21	COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OF YOUNGER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM)
	Willis M1, Borg S1, Persson U1, Neslusan C2
	1The Swedish Institute for Health Economics, IHE, Lund, Sweden, 2Johnson & Johnson, L.L.C, Raritan, NJ, USA

PDB22	EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SPAIN AND ITALY
	Erny-Albrecht K1, Goodall G1, Townsend C2, Kotchie R3, Nielsen S2, Valentine WJ1
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB23	COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN A POLISH SETTING
	Aristides M1, Kotchie R1, Nielsen S2, Townsend C2, Valentine WJ3, Scheijbeler H1
	1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

PDB24	A PHARMACOECONOMIC COMPARISON BETWEEN ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH DIABETIC NEPHROPATHY
	Stafylas P1, Sarafidis P1, Aletras V2
	1AHEPA University Hospital, Thessaloniki, Greece, 2University of Macedonia, Thessaloniki, Greece

PDB25	COST-EFFECTIVENESS OF DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A BELGIUM SETTING. A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS
	Scheijbeler H1, Aagren M2, Nielsen S2, Goodall G3, Kotchie R1, Valentine WJ3
	1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

PDB26	COSTS AND NEONATAL OUTCOMES AFTER INSULIN ASPART COMPARED WITH HUMAN INSULIN IN PREGNANT WOMEN WITH TYPE 1 DIABETES
	Lloyd AC1, Twena N2, Townsend C3, Holman AJ1
	1Fourth Hurdle Consulting, London, UK, 2Novo Nordisk Ltd, Crawley, West Sussex, UK, 3Novo Nordisk A/S, Virum, Denmark

PDB27	COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN CHINA
	Lynch M1, Scheijbeler H2, Kotchie R2, Nielsen S3, White J4, Valentine WJ5
	1IMS Health, Shanghai, China, 2IMS Health, London, UK, 3Novo Nordisk A/S, Virum, Denmark, 4Novo Nordisk International Operations A/S, Zurich, Switzerland, 5IMS Health, Basel, Switzerland

PDB28	COST-EFFECTIVENESS ANALYSIS OF ACARBOSE IN THE PREVENTION OF TYPE 2 DIABETES IN SOUTH KOREA
	JongMann K1, Clegg JP2, Chang K1, JuYeol P1, Wittrup-Jensen KU3, Valentine WJ2
	1Bayer, Seoul, South Korea, 2IMS Health, Basel, Switzerland, 3Bayer Schering Pharma AG, Berlin, Germany

PDB29	THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS AND THE COMBINED EFFECT OF HBA1C AND HYPOGLYCAEMIA REDUCTION
	McEwan P1, Mehin N2, Tetlow AP3, Sharplin P3
	1Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3Cardiff Research Consortium, Cardiff, South Glamorgan, UK

PDB30	EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN A SPANISH SETTING
	Tucker D1, Valentine WJ1, Nielsen S2, Townsend C2, Kotchie R3, Scheijbeler H3
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB31	TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES
	Baran RW, Xu Y, Vallarino C, Pandya B
	Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

PDB32	EVALUATING THE LONG-TERM CLINICAL AND ECONOMIC IMPLICATIONS OF CONVERTING TYPE 2 DIABETES PATIENTS TO INSULIN DETEMIR (± ORAL HYPOGLYCEMIC AGENTS) FROM INSULIN GLARGINE BASED REGIMENS IN GERMANY; DATA FROM THE PREDICTIVE STUDY
	Valentine WJ1, Goodall G1, Aagren M2, Nielsen S2, Kotchie R3
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB33	COST EFFECTIVENESS OF JANUVIA VERSUS AVANDIA AS SUPPLEMENTARY TREATMENT IN COMBINATION WITH METFORMIN FOR PATIENTS WITH TYPE 2 DIABETES
	Verheggen BG1, Van der Steen A1, Heeg BMS1, Vos CBJ2, Van Hout BA1
	1Pharmerit BV, Rotterdam, The Netherlands, 2Merck Sharp & Dohme BV, Haarlem, The Netherlands

PDB34	LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROM THE PREDICTIVE STUDY
	Palmer JL1, Goodall G1, Aagren M2, Nielsen S2, Kotchie R3, Valentine WJ1
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB35	ECONOMIC ANALYSIS OF THE TREATMENT WITH INSULIN GLARGINE PLUS ORAL ANTIDIABETICS (BOT) COMPARED TO TWICE DAILY PREMIXED INSULIN (CT) BASED ON THE LAPTOP TRIAL
	Janka HU1, Hessel F2, Walzer S3, Mueller E3
	1Zentralkrankenhaus Bremen-Nord, Bremen, Germany, 2Sanofi-Aventis, Berlin, Germany, 3Analytica International, Loerrach, Germany

PDB36	INSULIN USE AND COSTS OF CARDIOVASCULAR DISEASE EVENTS (CVD) AMONG PATIENTS WITH TYPE 2 DIABETES
	Engel-Nitz NM1, Gomez Rey G1, Sun P2, Rayl T1
	1i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA, 2Lilly Research Laboratories, Indianapolis, IN, USA

PDB37	MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS
	Goodall G1, Nielsen S2, Townsend C2, Kotchie R3, Erny-Albrecht K1, Valentine WJ1
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB38	COST OF ILLNESS STUDY OF TYPE-2 DIABETES IN COLOMBIA
	Einarson TR1, Walker J2, Gonzalez JC3
	1University of Toronto, Toronto, ON, Canada, 2Brock University, Faculty of Business, JH and St.-Catherines, ON, Canada, 3Merck Sharp & Dohme, Bogota, Colombia

PDB39	IMPACT OF HBA1C IN TYPE 2 DIABETES MELLITUS IN MEXICO: SIMULATION ANALYSIS, A PHARMACOECONOMIC PERSPECTIVE
	Castañeda RCL1, Sil MJSA1, Acevedo GAR1, Manterola SOMC2, Ramírez JR3, Rios LRN3, Romero SR4, Barquera SB5
	1Hospital Carlos Mc Gregor Sánchez Navarro. IMSS, Mexico City, Mexico, 2Sanofi-Aventis de México, Mexico City, Mexico, 3National Institute of cardiology "Ignacio Chavéz", Mexico City, Mexico, 4Instituto Mexicano del Seguro Social, Zona poniente, Toluca, Mexico, 5National Institute of Public Health, Cuernavaca, Morelos, Mexico

PDB40	SIMULATION OF LONG-TERM COSTS OF COMPLICATIONS IN TYPE II DIABETES IN THE UNITED STATES
	Ward A, Kongnakorn T, Moller J, O'Brien JA, Caro JJ
	Caro Research Institute, Concord, MA, USA

PDB41	INSULIN AND INSULIN ANCILLARY USAGE, THE ANNUAL COST OF TREATING TYPE 2 DIABETES WITH INSULIN IN THE UK
	Chandler F1, Ambery PD2, De Silva K3, Mulley PJ1
	1Glaxo SmithKline Pharmaceuticals, Uxbridge, Middlesex, UK, 2GlaxoSmithKline Europe, Uxbridge, Middlesex, UK, 3IMS Health, Camden, London, UK

PDB42	COSTS ASSOCIATED WITH THE FIRST SIX MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY
	Timlin L1, Tynan A1, Simpson A1, Liebl A2, Jones S3
	1Eli Lilly and Company Limited, Surrey, UK, 2Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany, 3The James Cook University Hospital, Middlesborough, UK

PDB43	COMPARATIVE STUDY OF ANNUAL TREATMENT COSTS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
	Alvarez Guisasola F1, Casal LLorente C2, Rubio-Terrés C3, Betegon L4, Echevarria A5
	1Centro de Salud la Calzada, Gijón, Asturias, Spain, 2Centro de Salud Villagarcía de Arosa, Pontevedra, Spain, 3HERO Consulting, Madrid, Spain, 4IMS HEOR, Madrid, madrid, Spain, 5sanofi-aventis, Madrid, madrid, Spain

PDB44	INPATIENT COSTS AND HEALTH OUTCOMES FOR PREGNANT WOMEN WITH TYPE 1 DIABETES
	Holman AJ1, Munro V2, Nielsen S3, Lloyd AC1
	1Fourth Hurdle Consulting, London, UK, 2Novo Nordisk Ltd, Crawley, West Sussex, UK, 3Novo Nordisk Ltd, Virum, Sweden

PDB45	THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND DIABETES-RELATED COSTS: EVIDENCE FROM A CLAIMS DATABASE
	Lage MJ1, Boye KS2
	1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB46	COST-UTILITY OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A FRENCH SETTING. A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS
	Scheijbeler H1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3, Kotchie R1
	1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

PDB47	LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH INSULIN ASPART VERSUS HUMAN BOLUS INSULIN IN TYPE 2 DIABETES PATIENTS IN THE SWEDISH SETTING
	Valentine WJ1, Goodall G1, Townsend C2, Kotchie R3, Nielsen S2, Erny-Albrecht K1
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB48	A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES
	Colclough HA1, Aagren M2, Hammer M2
	1Adelphi Group Products, Chesire, UK, 2Novo Nordisk A/S, Bagsværd, Denmark

PDB49	ESTIMATE OF HEALTH CARE RESOURCES NEEDED TO INITIATE INSULIN – RELATIVE COSTS OF DIFFERENT OPTIONS IN UK CLINICAL PRACTICE
	McKendrick J, Chetty M, Watkins J
	Eli Lilly and Company Limited, Basingstoke, UK

PDB50	UTILIZING OF CLAIMS DATABASES FOR IMPROVEMENT OF PRESCRIPTION HABITS FOR DIABETES MELLITUS TYPE 2
	Ilavska A1, Tomek D2, Hrmova D3, Tesar T4
	1Railway Hospital, Bratislava, Slovak Republic, 2Health Insurance Fund Apollo, Bratislava, Slovak Republic, 3GSK, Bratislava, Slovak Republic, 4Comenius University, Bratislava, Slovak Republic

PDB51	DRUG USE FOR DIABETES MELLITUS TYPE 2 AND ITS COMPLICATIONS IN SLOVAKIA
	Ilavska A1, Koren B2, Hrmova D3, Tesar T4, Glatz P5
	1Railway Hospital, Bratislava, Slovak Republic, 2Health Insurance Fund Apollo, Bratislava, Slovak Republic, 3GSK, Bratislava, Slovak Republic, 4Comenius University, Bratislava, Slovak Republic, 5Janssen-Cilag, Bratislava, Slovak Republic

PDB52	FACTORS ASSOCIATED WITH THE CHOICE OF A GLITAZONES OR SULFONYLUREA AS ADD ON TO ONGOING METFORMIN MONOTHERAPY
	Mavros P, Yin D, Krishnarajah G
	Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB53	AN EVALUATION OF TREATMENT DISCONTINUATION PATTERNS IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES SWITCHED TO ALTERNATIVE SHORT ACTING INSULIN REGIMENS IN UK GENERAL PRACTICE
	Currie CJ1, Poole C2, Tynan A3, Simpson A3
	1Cardiff University, Cardiff, UK, 2Pharmatelligence Limited, Cardiff, UK, 3Eli Lilly and Company Limited, Surrey, UK

PDB54	FACTORS ASSOCIATED WITH CONTINUED CLINICAL INERTIA AMONG PATIENTS WITH TYPE 2 DIABETES
	Lafata JE1, Dobie E1, Divine G1, McCarthy B2, Ulcickas Yood M3
	1Henry Ford Hospital, Detroit, MI, USA, 2Allina Medical Clinic, Minneapolis, MN, USA, 3Yale University School of Medicine, Hamden, CT, USA

PDB55	IMPACT ON HEALTH CARE COST OF INCREASING BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES – A CROSS SECTIONAL STUDY IN UNITED STATES
	Colclough HA1, Hammer M2, Aagren M2, Miligan G1
	1Adelphi Group Products, Chesire, UK, 2Novo Nordisk A/S, Bagsværd, Denmark

PDB56	FACTORS RELATED TO CSII USE AND REASONS FOR DISCONTINUATION
	Seereiner S1, Neeser K2, Weber C2, Schreiber K3, Habacher W1, Rakovac I1, Beck P1, Pieber TR1
	1Joanneum Research, Graz, Austria, 2Institute for Medical Informatics and Biostatistics, Basel, Switzerland, 3Isoplan Market Research, Saarbrücken, Germany

PDB57	ADMINISTRATIVE CLAIMS ANALYSIS OF NEW EXENATIDE PATIENTS WITH TYPE 2 DIABETES
	Fabunmi R1, Misurski D2, Oglesby A2, Wade R3, Quimbo R3, Barron J3, Schroeder B1, Wintle M1
	1Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3HealthCore, Inc, Wilmington, DE, USA

PDB58	CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES
	Misurski D1, Oglesby A1, Wade R2, Quimbo R2, Schroeder B3, Wintle M3
	1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthCore, Inc, Wilmington, DE, USA, 3Amylin Pharmaceuticals, Inc, San Diego, CA, USA

PDB59	METHODOLOGICAL APPROACH ASSESSING AN ASSOCIATION OF THE SURROGATE PARAMETER BETA-CELL ACTIVITY AND PATIENT-RELEVANT OUTCOMES IN TYPE 2 DIABETIC PATIENTS
	Ulle T1, Fuchs SM1, Dieterle C2, Happich M3, Aidelsburger P1
	1CAREM GmbH, Sauerlach, Germany, 2University of Munich, Munich, Germany, 3Lilly Deutschland GmbH, Bad Homburg, Germany

PDB60	ASSOCIATION OF INADEQUATE METABOLIC CONTROL AND CO-MORBIDITIES AND HEALTH RESOURCE UTILIZATION IN PATIENTS WITH DIABETES MELLITUS IN A SPANISH POPULATION
	Sicras-Mainar A1, Navarro-Artieda R2, Velasco-Velasco S1, González P3, Fernández-de-Bobadilla J3, Sánchez C3
	1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 3Pfizer Spain, Alcobendas, Madrid, Spain

PDB61	VALIDATING THE EXTERNAL VALIDITY OF RANDOMIZED CONTROLLED TRAILS WITH OBSERVATIONAL STUDIES AND CAUSAL EFFECT METHODS (PROPENSITY SCORE, MARGINAL STRUCTURE MODEL AND DOUBLY ROBUST METHODS)
	Sun P
	Lilly Research Laboratories, Indianapolis, IN, USA

PDB62	LONG-TERM CLINICAL OUTCOMES OF INSULIN DETEMIR VERSUS NPH FOR TYPE I DIABETES PATIENTS IN SPAIN
	Kotchie R1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3
	1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland

PDB63	ESTIMATING THE LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN ASPART (NOVORAPID®) FROM HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE POLISH SETTING
	Erny-Albrecht K1, Goodall G1, Nielsen S2, Townsend C2, Kotchie R3, Valentine WJ1
	1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK

PDB64	WITHDRAWN



PDB65	THE PROSIT DISEASE MODELLING COMMUNITY - OPEN SOURCE DEVELOPMENT OF DECISION ANALYTIC DISEASE MODELS FOR TYPE 2 DIABETES
	Schramm W, Schöll M, Trinczek B, Weber C
	Heilbronn University, Heilbronn, Germany

PDB66	RETROSPECTIVE COMPARISON OF COMPLIANCE TO FIXED-DOSE COMBINATION VERSUS SINGLE AGENT COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
	Patel BV1, Leslie RS1, Aranda GA2, McCoy M2, Baran RW3, Xu Y3, Bron M3
	1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Takeda Pharmaceuticals America, Inc, Deerfield, IL, USA, 3Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

PDB67	PERSISTENCE PATTERNS WITH ORAL ANTI-HYPERGLYCEMIC DRUG TREATMENT IN NEWLY TREATED PATIENTS - A POPULATION-BASED STUDY
	Grégoire JP, Sirois C, Perez N, Demers É, Moisan J
	Université Laval, Québec, QC, Canada

PDB68	IS A MEASUREMENT-GUIDED INTERVENTION PROGRAM TO LENGTHEN PERSISTENCE WITH METFORMIN MONOTHERAPY COST EFFECTIVE IN TYPE 2 DIABETES?
	Kristanto P1, Tousset E1, Vrijens B2
	1Pharmionic Systems, Vise, Belgium, 2University of Liège, Vise, Belgium

PDB69	DETERMINANTS OF STOPPING TREATMENT WITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE
	Koerselman J1, van der Bij S1, Erkens JA1, Kessabi S2, Groot MT3, Penning-van Beest FJ1, Herings RM1
	1PHARMO Institute, Utrecht, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharma B.V, Arnhem, The Netherlands

PDB70	EVALUATING CLINICAL AND PATIENT-REPORTED OUTCOMES (PROS) FOR PATIENTS WITH DIABETES PARTICIPATING IN A COMPREHENSIVE DISEASE MANAGEMENT PROGRAM.
	Pinto SL1, Morgan EE2
	1University of Toledo, Toledo, OH, USA, 2Hamot Medical Center, Montville, OH, USA

PDB71	PILOT STUDY OF CLINICIAN ATTITUDES TO PUMP THERAPY: INTERNATIONAL DIFFERENCES AND THE NEED FOR A GREATER UNDERSTANDING OF THE PATIENT PERSPECTIVE
	Reaney M1, Barnard K2, Skinner TC3, Speight J1
	1AHP Research Ltd, Uxbridge, Middlesex, UK, 2University of Southampton, Southampton, UK, 3University of Wollongong, Wollongong, NSW, Australia

PDB72	EMPIRIC PSYCHOLOGICAL TYPING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED ORALLY, AND CORRESPONDING GLYCAEMIC CONTROL / RESULTS FROM THE SETT2D SURVEY
	Stridde E, Leverkus F
	Pfizer Pharma GmbH, Karlsruhe, Germany

PDB73	PSYCHOMETRIC EVALUATION OF THE DIABETES SYMPTOM CHECKLIST- REVISED (DSC-R): FACE, CONTENT AND CONSTRUCT VALIDITY
	Humphrey L1, Vardeva K2, Arbuckle R1, Viala M3, Scott J4, Snoek FJ5
	1Mapi Values Ltd, Bollington, Cheshire, UK, 2Global Health Outcomes, Greenford, Middlesex, UK, 3Mapi Values France, Lyon, France, 4Mapi Values Ltd, Boston, MA, USA, 5VU University Medical Centre, Amsterdam, The Netherlands

PDB74	EFFECTS OF AN INTENSIFIED THERAPY WITH INSULIN GLARGINE AND INSULINE GLULISINE ON PATIENT REPORTED OUTCOMES IN DIABETES MELLITUS
	Daikeler R1, Hoegy B2
	1Specialist in Internal Medicine, Diabetologist, Sinsheim, Germany, 2Sanofi-Aventis Germany GmbH, Bad Soden, Germany

PDB75	THE TRANSLATION AND LINGUISTIC VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) FOR USE IN EASTERN EUROPE
	Ellis G1, Wild D1, Christensen T2
	1Oxford Outcomes Ltd, Oxford, UK, 2Novo Nordisk A/S, Bagsværd, Denmark

PDB76	TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROL AND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
	Alvarez-Guisasola F1, Tinahones FJ2, Pfeiffer A3, Krishnarajah G4, Yin D5, Lyu R5, Mavros P5
	1Centro de Salud La Calzada II, Gijón, Spain, 2H.C.U. Virgen de la Victoria, Malaga, Malaga, Spain, 3Charite University Medical School Berlin, Berlin, Germany, 4Merck & Co, Whitehouse Station, NJ, USA, 5Merck & Co., Inc, Whitehouse Station, NJ, USA

PDB77	BARRIERS TO INSULIN THERAPY QUESTIONNAIRE: HOW TO USE THE “BIT” IN DAILY PRACTICE AND SCIENCE?
	Stridde E, Leverkus F
	Pfizer Pharma GmbH, Karlsruhe, Germany

PDB78	COMPARISONS BETWEEN ITEQ AND DTSQ IN A SAMPLE OF TYPE 2 DIABETES MELLITUS PATIENTS
	Moock J, Kubiak T, Dingler D, Kohlmann T
	University of Greifswald, Greifswald, Germany

PDB79	THE DIABETES MEDICATION SATISFACTION TOOL (DMSAT): DEVELOPMENT AND VALIDATION OF A NEW PATIENT-CENTERED OUTCOMES INSTRUMENT FOR CLINICIANS
	Anderson RT1, Balkrishnan R2
	1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

ENDOCRINE DISORDERS

PEN1

TIME-AND-MOTION EVALUATION OF DIFFERENT GROWTH HORMONE FORMULATIONS
Nickman N1, Haak SW1, Holtorf AP1, Joshi AV2, Brixner D3 1University of Utah, Salt Lake City, UT, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3The University of Utah College of Pharmacy, Salt Lake City, UT, USA

HEMATOLOGICAL DISORDERS

PHM1	ASSESSING PATIENTS' RISKS OF BLOOD TRANSFUSIONS: A LITERATURE REVIEW OF PUBLISHED INCIDENCE RATES
	Darba J1, Minoves A2, Arocho R3
	1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research, Barcelona, Spain, 3Amgen SA, Barcelona, Spain

PHM2	BUDGET IMPACT (BI) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND
	Steiner S1, Brock E1, Schneider H1, Ruckdaeschel S1, Troxler J2, Rohrbacher R1
	1HealthEcon Ltd, Basel, Switzerland, 2Vifor Ltd. Pharmaceutical Specialties, Villars-sur-Glâne, Switzerland

PHM3	CLINICO-ECONOMICAL ANALYSIS OF BORTEZOMIB VS DEXAMETHASONE IN RECURRENT OR TREATMENT-RESISTANT MULTIPLE MYELOMA IN RUSSIA
	Avksentieva M1, Vorobiev P2
	1Moscow Medical Academy named after M.I.Sechenov, Moscow, Moscow, Russia, 2Moscow Medical Academy named after M.I.Sechenov, Moscow, Russia

PHM4	CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEK VS FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS
	Vorobiev P, Nekrasova N, Dorkina A, Sura M
	Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia

PHM5	ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE – A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (PII) EVALUATION
	Soini EJ1, Hallinen TA1, Sirkka A2
	1ESiOR Ltd, Kuopio, Finland, 2Baxter Ltd, Helsinki, Finland

PHM6	COST-EFFECTIVENESS OF INTRAVENOUS IRON VERSUS ORAL IRON IN ANEMIA TREATMENT IN ONCOLOGY, CHRONIC KIDNEY DISEASE AND POST-PARTUM PATIENTS
	Glenngård AH1, Borg S1, Danielson BG2, Persson U1
	1The Swedish Institute for Health Economics, IHE, Lund, Sweden, 2University Hospital, Uppsala, Sweden

PHM7	COST SIMULATION OF NOVOSEVEN VERSUS FEIBA AND ITT-F8 FOR PRIMARY PROPHYLAXIS TREATMENT OF HAEMOPHILIA A/B PATIENTS WITH INHIBITORS
	Weatherall JH
	Novo Nordisk, Bagsværd, Denmark

PHM8	COST-MINIMIZATION ANALYIS OF DARBEPOETIN-&ALPHA; VERSUS EPOETIN-&BETA; IN DIALYSED PATIENTS: A LONG-TERM RETROSPECTIVE MONOCENTRIC ITALIAN STUDY
	Eandi M1, Giotta N2, Biamino E2, Pradelli L3, Iannazzo S3
	1Università di Torino, Turin, Italy, 2Ospedale Civile di Asti, Asti, Italy, 3Advanced Research Srl, Turin, Italy,

PHM9	COST OF ILLNESS OF DIFFUSE LARGE B-CELL LYMPHOMA IN RUSSIA
	Krysanov I1, Magomedova A2, Moiseeva TN2, Yagudina RI1, Khabriev RU1
	1Moscow Medical Academy, Moscow, Russia, 2Hematological Scientific Center of the Russian Academy of Medical Sciences, Moscow, Russia

PHM10	COST OF TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (MDS) IN GERMANY
	Kuehne FC1, Mittendorf T1, Voelkl M2, Lipp R3, Germing U4, Vioni-Niemeyer A2, Von der Schulenburg JM1
	1Leibniz University Hannover, Hannover, Germany, 2Celgene GmbH, Munich, Germany, 3Innovation Onkologie Research&Consulting (IORC) GmbH, Hamburg, Germany, 4University of Düsseldorf, Düsseldorf, Germany

PHM11	COST UTILITY OF KNEE SURGERY WITH RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN HEMOPHILIA PATIENTS WITH INHIBITORS: AN EXPLORATORY MODEL
	Botteman MF1, Ballal R2, Joshi AV3
	1PharMerit North America LLC, Bethesda, MD, USA, 2Georgetown University, Washington, DC, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

PHM12	COST-EFFECTIVENESS OF DASATINIB VS IMATINIB 800 MG/DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN
	Brosa M1, Taylor MJ2, Staginnus U3, Meno Duran A3, Cerri KH4, Cervantes F5
	1Oblikue Consulting, Barcelona, Spain, 2University of York, York, UK, 3Bristol-Myers Squibb, Madrid, Spain, 4Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 5Hospital Clínic, Barcelona, Spain

PHM13	THE EFFECT OF RESTRICTING FERTILITY SERVICES IN GERMANY
	Dietrich ES, Bestmann B, Zierold F
	TK Scientific Institute for Benefit and Efficiency in Health Care, Hamburg, Germany

PHM14	PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) CHALLENGE TRANSFUSION RESOURCES NOW AND IN THE FUTURE
	Plesnila-Frank C1, Rottenkolber D2, Berger K2
	1MERG, Medical Economics Research Group, Munich, Germany, 2University Hospital of Munich, Munich, Germany

PHM15	POSITIVE INVESTMENT INTERVAL (PII) AND PAYBACK PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN HEALTH TECHNOLOGY INVESTMENT DECISIONS: PII IS A MATTER OF BEING AND PP IS A MATTER OF TURNING BENEFICIAL – A CASE OF HEMOPHILIA A
	Soini EJ
	ESiOR Ltd, Kuopio, Finland

PHM16	PHARMACOKINETIC-PHARMACODYNAMIC-PHARMACOECONOMIC (P3) MODELING TO INFORM PHARMACOGENOMIC TRIAL DESIGN AND RISK MANAGEMENT
	Veenstra DL, Salinger DH, Garrison LP, Shen DD, Vicini P
	University of Washington, Seattle, WA, USA

PHM17	RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) VS. ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) FOR ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS WITH INHIBITORS: A SYSTEMATIC REVIEW AND BAYESIAN META-REGRESSION SURVIVAL MODEL WITH TIME-DEPENDENT COVARIATES
	Treur MJ1, McCracken F1, Heeg B1, Joshi AV2, Botteman MF3, De Charro F1, Van Hout BA1
	1Pharmerit Europe, Rotterdam, Zuid-Holland, The Netherlands, 2Novo Nordisk Inc, Princeton, NJ, USA, 3PharMerit North America LLC, Bethesda, MD, USA

PHM18	BEST-WORST CASE SCALING IN DISCRETE CHOICE EXPERIMENTS: AN APPLICATION IN A RARE DISEASE POPULATION
	Lee WC1, Joshi AV2, Pashos CL3
	1Abt Associates Inc, Bethesda, MD, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3Abt Associates Inc, Lexington, MA, USA

PHM19	USING THE EQ-5D TO MONITOR HEALTH-RELATED QUALITY OF LIFE OVER TIME IN THE CATALAN HEALTH INTERVIEW SURVEY
	Herdman M1, Ferrer M2, Rajmil L3, Brugulat P4, Vilagut G2, Medina A4, Cunillera O2, Tresserras R4, Alonso J2
	1CIBER en Epidemiologia y Salud Pública (CIBERESP), Barcelona, Cataluña, Spain, 2IMIM-Hospital del Mar, Barcelona, Cataluña, Spain, 3Agency for Quality, Research, and Assessment (AQuRA) in Health, Barcelona, Cataluña, Spain, 4Departament de Salut, Barcelona, Cataluña, Spain

PHM20	VALUE OF TRANSFUSION-FREE LIVING IN MDS: RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS
	Goss TF1, Szende A2, Schaefer C1, Knight R3, Heptinstall K4, Lübbert M5, Deschler B5, Fenaux P6, Mufti GJ7, Killick S8, List A9
	1Covance Market Access, Gaithersburg, MD, USA, 2Covance Market Access, Leeds, UK, 3Celgene Corporation, Summit, NJ, USA, 4MDS Foundation, Crosswicks, NJ, USA, 5University of Freiburg, Freiburg, Germany, 6Hôpital Avicenne, University of Paris XIII, Bobigny, France, 7King’s College Hospital, London, UK, 8Royal Bournemouth Hospital Foundation Trust, Bournemouth, UK, 9University of South Florida, Tampa, FL, USA

PHM21	UK COMMUNITY DERIVED UTILITIES USING TIME TRADE OFF FOR ORAL VERSUS SUBCUTANEOUS IRON CHELATION THERAPY FOR THE TREATMENT OF CHRONIC IRON OVERLOAD
	Tolley K1, Oyee J1, Jewitt K2, Ossa DF2
	1Mapi Values, Bollington, Cheshire, UK, 2Novartis Pharmaceuticals UK Limited, Frimley, Surrey, UK

PHM23	PATIENTS', PHYSICIANS' AND PHARMACISTS' PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES TO TREAT PATIENTS WITH INHIBITORS: A DISCRETE CHOICE EXPERIMENT
	Borghetti F1, Scalone L1, Gringeri A2, V. Mackensen S3, Mantovani LG4
	1Center of Pharmacoeconomics, University of Milan, Milan, Italy, 2Regina Elena Hosp. and Univ. of Milan, Milan, Italy, 3University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, 4University of Naples, Federico II, Naples, Italy

MENTAL HEALTH

PMH1	PRESCRIBING PATTERNS, PREDICTORS, AND COSTS ASSOCIATED WITH ANTIDEPRESSANT TREATMENTS FOR PERSONS WITH MAJOR DEPRSSIVE DISORDER (MDD) AND COMORBID PAIN
	Becker MA1, Ochshorn E1, Diamond R2
	1University of South Florida, Tampa, FL, USA, 2University of Wisconsin, Madison, WI, USA

PMH2	A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN GERMANY
	Hoffman DL1, Mychaskiw MA2
	1Deborah Hoffman, PhD, LLC, New Haven, CT, USA, 2Pfizer, Inc, New York, NY, USA

PMH3	EFFECTIVENESS OF OLANZAPINE TREATMENT FOR SCHIZOPHRENIA: 12-MONTH RESULTS OF THE POST MARKETING SURVEILLANCE IN JAPAN
	Nakahara N1, Takagaki N1, Fujikoshi S1, Kuramochi M1, Kamae I2, Takahashi M1
	1Eli Lilly Japan K.K, Kobe, Japan, 2Kobe University Graduate School of Medicine, Kobe, Japan

PMH4	EFFICACY OF ANTIPSYCHOTICS IN NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
	Darba J1, Frigola A2, Rojo E3, Rejas J4
	1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research, Barcelona, Spain, 3Granollers General Hospital, Granollers, Barcelona, Spain, 4Pfizer Spain, Madrid, Spain

PMH5	THE COMPARATIVE EFFICACY OF SECOND-GENERATION ANTIDEPRESSANTS FOR THE ACUTE-PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
	Gartlehner G1, Hansen R2, Thieda P2, Gaynes BN2, DeVeaugh-Geiss A2, Krebs EE3, Lohr KN4
	1Ludwig Boltzmann Institute for Health Technology Assessments, Vienna, Austria, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Indiana University, Bloomington, IN, USA, 4RTI-International, Research Triangle Park, NC, USA

PMH6	ATTAINING REMISSION OF DEPRESSIVE SYMPTOMS IN THE PIVOTAL RANDOMISED CLINICAL TRIALS OF DULOXETINE IN MAJOR DEPRESSION. WHICH ARE THE MOST EFFICACIOUS DOSES?
	Ballesteros J, Callado LF, Gutierrez M
	University of the Basque Country, UPV-EHU, Leioa, Vizcaya, Spain

PMH7	TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: RESULTS ACROSS WORLD GEOGRAPHIES
	Zhu B1, Montgomery W2, Ascher-Svanum H1, Faries D1, Stephenson DA3, McKendrick J3, Brnabic A4, Marder SR5
	1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Sydney, NSW, Australia, 3Eli Lilly and Company, UK of Great Britain, London, UK, 4Eli Lilly and Company, North Ryde, Australia, Australia, 5Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA

PMH8	RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CANADA
	Costigan N1, Ligate L2, Povey M3, Lam A4
	1University of Alberta, Red Deer, ON, Canada, 2Cambridge Memorial Hospital, Cambridge, ON, Canada, 3SGS Life Science Services Belgium, Wavre, Belgium, 4Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH9	TREATMENT RETENTION WITH RISPERIDONE LONG ACTING INJECTION (RLAI) IN EUROPEAN PATIENTS WITH SCHIZOPHRENIA: 12-MONTH INTERIM RESULTS FROM ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
	Olivares JM1, Peuskens J2, Pecenak J3, Tuma I4, Van Kooten M5, Eriksson L6, Povey M7, Lam A8, Zhao Z9
	1Servicio de Psiquiatria Hospital, Vigo, Spain, 2Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 3FNSP Bratislava, Bratislava, Slovak Republic, 4FNSP Hradec Kralove, Hradec Kralove, Czech Republic, 5Ambulant ACT, Hoofddorp, The Netherlands, 66SU/Östra RPV, Hisings-Backa, Sweden, 7SGS Life Science Services Belgium, Wavre, Belgium, 8Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada, 9Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

PMH10	REDUCTION IN SUICIDAL IDEATION, VIOLENT BEHAVIOUR, AND SELF INJURY AFTER TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA
	Tuma I1, Pecenak J2, Povey M3, Lam A4
	1FNSP Hradec Kralove, Hradec Kralove, Czech Republic, 2FNSP Bratislava, Bratislava, Slovak Republic, 3SGS Life Science Services Belgium, Wavre, Belgium, 4Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH11	RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 12 MONTH PRELIMINARY RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA
	Pecenak J1, Tuma I2, Povey M3, Lam A4
	1FNSP Bratislava, Bratislava, Slovak Republic, 2FNSP Hradec Kralove, Hradec Kralove, Czech Republic, 3SGS Life Science Services Belgium, Wavre, Belgium, 4Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH12	24-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI) VERSUS ORAL ANTIPSYCHOTICS: RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN SPAIN
	Olivares JM1, Diels J2, Rodriguez-Morales A3, Zhao Z4, Lam A5
	1Servicio de Psiquiatria Hospital, Vigo, Spain, 2Janssen Pharmaceutica, Beerse, Belgium, 3Janssen-Cilag, Spain, Madrid, Spain, 4Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA, 5Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH13	IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): 18 MONTH INTERIM RESULTS FROM BELGIAN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
	Peuskens J1, Povey M2, Van der Veken J3, Lam A4
	1Universitair Psychiatrisch Centrum, KUL Leuven, Leuven, Belgium, 2SGS Life Science Services Belgium, Wavre, Belgium, 3Janssen Cilag, Berchem, Belgium, 4Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH14	REMISSION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): 12 MONTH INTERIM RESULTS FROM E-STAR PROJECT IN CZECH REPUBLIC AND SLOVAKIA
	Tuma I1, Pecenak J2, Povey M3, Lam A4
	1FNSP Hradec Kralove, Hradec Kralove, Czech Republic, 2FNSP Bratislava, Bratislava, Slovak Republic, 3SGS Life Science Services Belgium, Wavre, Belgium, 4Johnson and Johnson Pharmaceutical Services, Toronto, ON, Canada

PMH15	PREVALENCE OF TREATMENT RESISTANT DEPRESSION IN USUAL CARE IN THE UNITED STATES
	Stensland M, Zhu B, Shaywitz JE
	Eli Lilly and Company, Indianapolis, IN, USA

PMH16	ASSOCIATION BETWEEN ATYPICAL ANTIPSYCHOTIC USE AND TREATMENT-EMERGENT DIABETES, HYPERLIPIDEMIA, AND OBESITY
	Lingle EW1, Dickson M2
	1University of South Carolina, Columbia, SC, USA, 2University of South Carolina, College of Pharmacy, Columbia, SC, USA

PMH17	COSTS OF PRESCRIPTION OPIOID ABUSE
	White AG, Birnbaum HG
	Analysis Group, Inc, Boston, MA, USA

PMH18	PRESCRIBING PATTERN OF CITALOPRAM AND ESCITALOPRAM IN THE CANTON OF GENEVA: A POTENTIAL FOR MAJOR SAVINGS
	Girardin F1, Vernaz-Hegi N2, Muscionico D3, Salomon JL3, Schulz P1, Bonnabry P2
	1Clinical psychopharmacology Unit, Geneva University Hospitals, Chêne-Bourg, Geneva, Switzerland, 2Pharmacy, Geneva University Hospitals, Geneva 14, Switzerland, 3OFAC, Geneva, Switzerland

PMH19	COMORBIDITY AND COSTS IN GENERALIZED ANXIETY DISORDERS AND FIBROMYALGIA SYNDROME IN THE PRIMARY CARE SETTING (PCS): A COMPARISON OF TWO DISORDERS WITH HIGH DEMAND OF CARE
	Blanca-Tamayo M1, Sicras-Mainar A2, Navarro-Artieda R3, Rejas-Gutiérrez J4
	1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 3Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 4Pfizer Spain, Madrid, Spain

PMH20	RESOURCE USE AND COSTS ASSOCIATED WITH CHANGES IN ANTIDEPRESSANT TREATMENT IN A MANAGED CARE POPULATION WITH MAJOR DEPRESSIVE DISORDER
	Schultz JS1, Joish VN2
	1University of Minnesota Duluth, Duluth, MN, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA

PMH21	THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE IN SWEDEN
	Damen J1, Heeg B1, Lothgren M2, Van Hout BA1
	1Pharmerit BV, Rotterdam, Zuid-Holland, The Netherlands, 2Janssen-Cilag, Sollentuna, Sweden

PMH22	A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS
	Damen J1, Heeg B1, Lothgren M2, Van Hout BA1
	1Pharmerit BV, Rotterdam, Zuid-Holland, The Netherlands, 2JANSSEN-CILAG, Sollentuna, Sweden

PMH23	COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US
	Ascher-Svanum H1, Furiak NM2, Klein RW2, Smolen LJ2, Zhu B1
	1Eli Lilly and Company, Indianapolis, IN, USA, 2Medical Decision Modeling Inc, Indianapolis, IN, USA

PMH24	THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY
	Damen J1, Heeg B1, Lothgren M2, Van Hout BA1
	1Pharmerit BV, Rotterdam, Zuid-Holland, The Netherlands, 2Janssen-Cilag, Sollentuna, Sweden

PMH25	COST EFFETIVENESS OF AMISULPRID IN THE TREATMENT OF SCHIZOPHRENIA
	Dardzinski W1, Pawlik D1, Walczak J1, Lis J2, Nogas G1
	1Arcana Institute, Cracow, Poland, 2Sanofi-Aventis, Polska, Warsaw, Poland

PMH26	WITHDRAWN



PMH27	COST-EFFECTIVENESS OF DULOXETINE VS. VENLAFAXINE XR AND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN
	De Cock E1, Benedict A2, Le TK3, Sacristán del Castillo JA4, Dilla T5
	1United BioSource Corporation, Barcelona, Spain, 2United BioSource Corporation, Budapest, Hungary, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Lilly S.A, Madrid, Spain, 5Eli Lilly Spain, Alcobendas, Spain

PMH28	A PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM VS. PAROXETINE IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER IN NORWAY
	Danchenko N1, Mæhlum E2, Hansen K3, Despiegel N3, Holsten F4
	1Lundbeck SAS, Paris, France, 2Lundbeck, Lysaker, Norway, 3H. Lundbeck A/S, Paris, France, 4University of Bergen, Bergen, Norway

PMH29	SWITCHING FROM BRANDED TO GENERIC RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA: AN ESTIMATION OF POTENTIAL ECONOMIC CONSEQUENCES IN THE NETHERLANDS
	Van Nooten F1, Rijnders C2, Brown R3, Van Agthoven M4
	1United BioSource Corporation, Brussels, Flanders, Belgium, 2Institute for Mental Health Care Midden Brabant, Tilburg, Noord-Brabant, The Netherlands, 3United BioSource Corporation, London, London, UK, 4Janssen-Cilag BV, Tilburg, The Netherlands

PMH30	DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE
	Luppa M1, Heinrich S1, Matschinger H1, Hensel A1, Luck T1, Kaduszkiewicz H2, Riedel-Heller SG1, Koenig HH1
	1University of Leipzig, Leipzig, Saxony, Germany, 2University of Hamburg, Hamburg, Hamburg, Germany

PMH31	A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN THE UK (UK)
	Hoffman DL1, Mychaskiw MA2
	1Deborah Hoffman, PhD, LLC, New Haven, CT, USA, 2Pfizer, Inc, New York, NY, USA

PMH32	HEALTH RESOURCES CONSUMPTION AND COST OF MANIC EPISODE IN SPAIN
	Tafalla M, Cordero L, Diez T, Hernandez R
	AstraZeneca, Madrid, Spain

PMH33	AN EVALUATION OF HEALTH CARE COSTS WITH A DISEASE MANAGEMENT PROGRAM FOR ADULTS WITH SCHIZOPHRENIA IN A MEDICAID POPULATION USING PROPENSITY SCORE MATCHING
	Skrepnek GH1, Armstrong EP1, Brookler K2, Roper J2, Martin BE2, Karabatsos L2, Hunter C2
	1University of Arizona, Tucson, AZ, USA, 2Colorado Department of Health Care Policy and Financing, Denver, CO, USA

PMH34	A PHARMACOECONOMIC OUTCOMES ANALYSIS COMPARING RISPERIDONE LONG-ACTING INJECTION AND CONVENTIONAL DEPOT ANTIPSYCHOTICS
	Snaterse M, Welch R
	Capital Health, Edmonton, AB, Canada

PMH35	SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND: A COST ANALYSIS
	Hansen K1, Sapin C2, Toumi M1
	1H. Lundbeck A/S, Paris, France, 2Lundbeck SAS, Paris, France

PMH36	A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST CURRENT STIMULANT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY
	Diamantopoulos A1, Lorenzo M2, Happich M3, Cottrell S1, Scheijbeler H1
	1IMS Health, London, UK, 2Eli Lilly and Company Limited, Windlesham, Surrey, UK, 3Lilly Deutschland GmbH, Bad Homburg, Germany

PMH37	PAIN IN DEPRESSION AND PRODUCTIVITY LOSS – (RESULTS FROM UK SUBSET OF THE EUROPEAN FACTORS INFLUENCING DEPRESSION ENDPOINTS RESEARCH (FINDER) STUDY)
	Azough A1, Das Gupta R1, Wong B1, Barradell CA2, Quail D3, Jogessar Y2
	1Boehringer Ingelheim, Bracknell, Berkshire, UK, 2Eli Lilly and Company, Basingstoke, Hampshire, UK, 3Eli Lilly and Company Limited, Surrey, UK

PMH38	INFLUENCE OF BEHAVIOURAL SYMPTOMS ON RESOURCES USE IN DEMENTIA
	Orgogozo JM1, Gaichies S2, Dartigues JF2, Guennec M3, Rive B4, Armand C5, Guilhaume C4
	1Bordeaux University Hospital, Bordeaux, France, 2Inserm U593, Victor Segalen Bordeaux 2 University, Bordeaux, France, 3Lundbeck SA, Paris, France, 4Lundbeck SAS, Paris, France, 5H. Lundbeck A/S, Paris, France

PMH39	ESTIMATION OF THE RESOURCE UTILIZATION AND METABOLIC CONTROL ASSOCIATED WITH DEPRESSIVE SYNDROME IN PATIENTS WITH STROKE
	Sicras A1, Blanca M2, Navarro R1, F Bobadilla J3, González P4, Sánchez C4
	1Badalona Servicios Asistenciales, Barcelona, Spain, 2Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 3Pfizer Spain, Madrid, Spain, 4Pfizer Spain, Alcobendas, Madrid, Spain

PMH40	IMPACT OF AN INSPECTOR'S STAMP APPROVAL POLICY INTO THE ATYPICAL ANTIPSYCHOTIC MARKET IN ANDALUSIA (SPAIN)
	Badia X, Vieta A, Lara N, Giménez E
	IMS Health, Barcelona, Spain

PMH41	A MULTI-CENTER STUDY OF ANTIPSYCHOTIC MEDICATION USE, TREATMENT DYNAMICS AND PATIENT SYMPTOMATOLOGY IN SPAIN. RESULTS FROM ANTIPSYCHOSISMONITOR INITIATIVE
	Narayanan S1, Pedrosa RG2
	1TNS Healthcare, Stamford, CT, USA, 2TNS Healthcare, Madrid, Madrid, Spain

PMH42	THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS WITHIN ONTARIO DRUG BENEFIT CLAIMS
	Glass JR, Lal K, Luong D
	Janssen-Ortho Inc, Toronto, ON, Canada

PMH43	POTENTIAL DRUG-DRUG INTERACTIONS WITH RISPERIDONE AND THE RISK OF DISCONTINUATION: A RETROSPECTIVE ANALYSIS OF PATIENTS IN QUEBEC, CANADA
	Ishak KJ1, Glass JR2, Tan Y1, Luong D2, Caro JJ3
	1Caro Research Institute, Montreal, QC, Canada, 2Janssen-Ortho Inc, Toronto, ON, Canada, 3Caro Research Institute, Concord, MA, USA

PMH44/ ES2	COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA
	Leeuwenkamp O1, Morlock R2, Bell CF3, Brogan A4, Mauskopf J4
	1NV Organon, Molenstraat, Oss, The Netherlands, 2Pfizer Inc, Ann Arbor, MI, USA, 3GlaxoSmithKline, Memphis, TN, USA, 4RTI Health Solutions, Research Triangle Park, NC, USA

PMH45	THE IMPACT OF CHANGES IN ANTIDEPRESSANT DRUG TREATMENT IN ELDERLY NURSING HOME (NH) PATIENTS- AREAS OF POTENTIAL CARE DETERIORATION DUE TO FORMULARY POLICIES: RESULTS FROM A PILOT STUDY
	Erder MH1, Fridman M2, Tourkodimutris S1
	1Forest Research Institute, Jersey City, NJ, USA, 2AMF Consulting, Inc, Los Angeles, CA, USA

PMH46	THE SENSITIVITY TO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ASBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS
	Ballesteros J1, Perez V2, Puigdemont D2, Callado LF1, Alvarez E2, Artigas F3
	1University of the Basque Country, UPV-EHU, Leioa, Vizcaya, Spain, 2Santa Creu i Sant Pau Hospital, Barcelona, Spain, 3Institut d'Investigacions Biomediques (CSIC-IDIBAPS), Barcelona, Spain

PMH47	DEVELOPING COST-EFFECTIVE FORMULARIES: IMPLICATIONS FOR NEW ATYPICAL ANTIPSYCHOTICS
	Trakas K1, Diels JK2, Nicholl D3, Nuyts G3
	1Johnson & Johnson, Toronto, ON, Canada, 2Janssen Pharmaceutica, Beerse, Belgium, 3Johnson & Johnson, Raritan, NJ, USA

PMH48	IMPACT OF COMORBIDITY ON EQ-5D : A STUDY OF HEALTH-RELATED QUALITY OF LIFE IN DEPRESSION IN A GENERAL POPULATION SURVEY
	Thuresson PO1, Kind P2, Bingefors K1
	1Uppsala University, Uppsala, Sweden, 2University of York, York, UK

PMH49	SF-36 AND EQ-5D QUALITY OF LIFE INSTRUMENTS IN MAJOR DEPRESSIVE DISORDER PATIENTS: COMPARISONS OF TWO DIFFERENT TREATMENT OPTIONS
	Ergun H1, Aydemir O2, Kesebir S3, Soygur H4, Tulunay FC5
	1Ankara University Faculty of Medicine, Ankara, Turkey, 2Celal Bayar Unversity Faculty of Medicine, Manisa, Turkey, 3Kirikkale State Hospital, Kirikkale, Turkey, 4Ankara Onkoloji Hospital, Ankara, Turkey, 5Ankara University Medical School, Ankara, Turkey

PMH50	A BELGIAN PILOT PROJECT TESTING THE FEASIBILITY AND ACCEPTABILITY OF SHORT MESSAGE SERVICE (SMS) TEXT MESSAGING TO PATIENTS TREATED WITH QUETIAPINE
	Lodewyck P1, Volcke D2, Snoeck P3, Festjens T4, Vandenhoven G5, Matthys A5
	1Psychiatric Ziekenhuis Heilige Familie, Kortrijk, Belgium, 2Kliniek OLV van Lourdes, Waregem, Belgium, 3Stedelijk Ziekenhuis, Roeselare, Belgium, 4Stedelijk Ziekenhuis, Roeselaere, Belgium, 5AstraZeneca Belgium, Brussels, Belgium

PMH51	ADHERENCE OF ALZHEIMER PATIENTS TO ANTIDEMENTIA DRUGS
	Schwalbe O1, Freiberg I2, Kloft C3
	1Freie Universitaet Berlin, Berlin, Germany, 2Freie Universitaet Berlin, Berlin, Berlin, Germany, 3Martin-Luther-Universitaet Halle-Wittenberg, Halle, Saxony-Anhalt, Germany

PMH52	WITHDRAWN



PMH53	ADHERENCE AND SWITCHING WITH ANTIDEPRESSANTS
	Varasteh LT, Pedan A, He Y
	Adheris, Inc, Burlington, MA, USA

PMH54	PRELIMINARY VALIDATION OF THE ENGLISH VERSION OF THE SCHIZOPHRENIA QUALITY OF LIFE (S-QOL) SCALE
	Auquier P1, Sapin C2, Robitail S1, Simeoni MC1
	1School of Medicine, Marseille, France, 2Lundbeck SAS, Paris, France

PMH55	DEVELOPMENT AND VALIDATION OF THE SLEEP IMPACT SCALE FOR INSOMNIA
	Crawford B1, Burgess S1, Burrell A2, Tellefsen C1
	1Mapi Values USA LLC, Boston, MA, USA, 2Sanofi Aventis, Paris, France

PMH56	A REVIEW OF INSTRUMENTS USED TO ASSESS THE IMPACT OF ALCOHOLISM ON QUALITY OF LIFE
	Reaney M1, Martin C2, Speight J1
	1AHP Research Ltd, Uxbridge, Middlesex, UK, 2Leeds Metropolitan University, Leeds, Leeds, UK

PMH57	EFFECTIVENESS OF A PSYCHOSOCIAL INTERVENTION PROGRAM FOR CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE IN THE PREVENTION OR REDUCTION CAREGIVER BURDEN. EDUCA STUDY
	Balañá M1, Martín M2, Pons S3, Gobartt AL1
	1Novartis Pharmaceuticals, Barcelona, Spain, 2Clinica Padre Menni, Pamplona, Spain, 3Laboratorios Esteve, Barcelona, Spain

PMH58	IMPROVED SLEEP IMPACT IN GENERALIZED ANXIETY DISORDER WITH ZOLPIDEM TARTRATE EXTENDED-RELEASE
	Crawford B1, Zhu Y1, Seal B2, Rosa K1
	1Mapi Values, Boston, MA, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA

PMH59	LINGUISTIC VALIDATION OF THE HADS FOR USE IN INTERNATIONAL STUDIES
	Grataloup G1, Ingham M2, Caleo S3, Coffey L4
	1Mapi Research Institute, Lyon, Rhone, France, 2Johnson and Johnson, Beerse, Belgium, 3Janssen Pharmaceutica N.V, Beerse, Belgium, 4NferNelson Publishing Company Ltd, London, UK

PMH60	A PHARMACOECONOMIC COMPARISON OF ESCITALOPRAM AND DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN THE UK
	Wade AG1, Fernandez JL2, François C3, Hansen K3, Despiegel N3, Danchenko N3
	1CPS Research, Glasgow, UK, 2London School of Economics, London, UK, 3H. Lundbeck A/S, Paris, France

PHM22	THE EMOTIONAL AND PHYSICAL BURDEN OF INJECTIONS ON PATIENTS UNDERGOING IVF
	Huisman D1, Hu L1, Raijmakers X2, Hoomans E2
	1SKIM, Rotterdam, The Netherlands, 2NV Organon, Oss, The Netherlands

RESPIRATORY DISORDERS

PRS1	ACUTE EFFECTS OF SILDENAFIL ON ECHOCARDIOGRAGHIC PARAMETERS IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION
	Behzad Nia N, Najafi Zadeh K, Sharif Kashani B, Shahabi P
	National Research Institute of Tuberclusis and Lung Disease (N. R. I. T. L. D), Tehran, Iran

PRS2	A COST-MINIMIZATION ANALYSIS COMPARING MOXIFLOXACIN VERSUS LEVOFLOXACIN AND CEFTRIAXONE FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA: RESULTS FROM THE MOTIV TRIAL
	Lloyd AC, Holman AJ
	Fourth Hurdle Consulting, London, UK

PRS3	COSTS OF COPD IN SWEDEN ACCORDING TO DISEASE SEVERITY
	Jansson SA1, Björkman J2, Lindberg A3, Rönmark E3, Lundbäck B1
	1Karolinska Institutet, Stockholm, Sweden, 2Boehringer Ingelheim AB, Stockholm, Sweden, 3The OLIN Studies, Luleå, Sweden

PRS4	RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS
	Jahnz-Rozyk K, Targowski T, From S
	Military Institute of Health Service, Warsaw, Poland

PRS5	REDUCTION IN TOTAL TREATMENT COSTS THROUGH IMPROVED PHARMACEUTICAL TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES
	Hallinen T1, Karjalainen J2, Hahl J3, Torvinen S3, Martikainen JA4
	1Centre for Pharmaceutical Policy and Economics (CEPPE), Kuopio, Finland, 2Suomen Terveystalo Oyj, Helsinki, Finland, 3GlaxoSmithKline Oy, Espoo, Finland, 4Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland

PRS6	ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL HYPERTENSION IN GERMANY: AN INTERIM ANALYSIS OF RESOURCE UTILISATION
	Ehlken B1, Plesnila Frank C1, Ghofrani HA2, Grimminger F2, Hoeper MM3, Stähler G4, Wilkens H5, Berger K1, Resch A6
	1MERG - Medical Economics Research Group, München, Germany, 2University Hospital Giessen and Marburg, Giessen, Germany, 3Hannover Medical School, Hanover, Germany, 4Klinik Löwenstein, Löwenstein, Germany, 5University Hospitals of the Saarland, Homburg/Saar, Germany, 6Pfizer Deutschland GmbH, Karlsruhe, Germany

PRS7	ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FOR TEXAS MEDICAID COPD PATIENTS
	Yarger SA, Rascati KL, Leslie RC
	The University of Texas at Austin, Austin, TX, USA

PRS8	S-MEDDIAL PROJECT OF COOPERATION WITH PEDIATRICIANS ON PROVIDING INDIVIDUAL FEEDBACK ON ANTIBIOTICS PRESCRIPTION IN ORDER TO IMPROVE PRESCRIPTION HABITS AND TO RATIONALIZE DRUG SPENDING
	Hupkova H1, Kochan J1, Gezo M1, Hrmova D2
	1General Health Insurance Fund, Bratislava, Slovak Republic, 2GSK, Bratislava, Slovak Republic

PRS9	ECONOMIC EFFECTS AND SUSTAINABILITY OF A STRUCTURED CARE PROGRAMME FOR COPD PATIENTS
	Keiner NR1, Schaefer M2
	1Hospital GPR Ruesselsheim, Ruesselsheim, Germany, 2Institut für Klinische Pharmakologie, Berlin, Germany

PRS10	TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE
	Asche CV1, Seal B2, McAdam-Marx C1, Crookston B3, Svedja R1, Mullins CD4
	1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3University of Utah, Salt Lake City, UT, USA, 4University of Maryland School of Pharmacy, Baltimore, MD, USA

PRS11	MARKOV MODEL FOR COPD: COMPARING TREEAGE AND ARENA SOFTWARE AND VALIDATING THE MODEL
	Menn P, Sun J, Holle R
	GSF - National Research Center for Environment and Health, Neuherberg, Germany

PRS12	MAPPING THE EQ-5D FROM THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN A CLINICAL TRIAL OF COPD TREATMENTS- RESULTS FROM THE OPTIMAL TRIAL
	Marra CA1, Sullivan SD2, Najafzadeh M1, Sadatsafavi M1, Jones PW1, Aaron S3, FitzGerald JM4
	1University of British Columbia, Vancouver, BC, Canada, 2University of Washington, Seattle, WA, USA, 3University of Ottawa, Ottawa, BC, Canada, 4The Lung Centre, Vancouver General Hospital, Vancouver, BC, Canada

PRS13	CEPOC STUDY: DIAGNOSTIC VALIDITY OF INDIRECT METHOS FOR COMPLIANCE ASSESSMENT IN COPD PATIENTS
	Garcia AJ1, Leiva F2, Barnestein P2, Vidal F2, Carrion MT2, Prados D2
	1Universidad de Malaga, Malaga, Spain, 2Servicio Andaluz De Salud, Malaga, Spain

PRS14	THE IMPACT OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION ON QUALITY OF LIFE OF ASTHMA AND COPD PATIENTS
	Casey J1, Redmond S2
	1Beaumont Park Clinic, Dublin 9, Ireland, 2GlaxoSmithKline, Dublin 16, Ireland

PRS15	EQ-5D UTILITIES ASSOCIATED WITH LEVELS OF COPD SEVERITY: A META-ANALYTIC APPROACH
	Wilke CT1, Jung E1, Lee TA2, Pickard AS3
	1University of Illinois at Chicago, Chicago, IL, USA, 2Hines VA Hospital and Northwestern University, Chicago, IL, USA, 3College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PRS16	DEVELOPMENT OF PREFERENCE-BASED EQ-5D UTILITY VALUES FOR THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE (SGRQ-COPD)
	Vardeva K1, Spencer MD2, Punekar Y3
	1GlaxoSmithKline, Greenford, Middlesex, UK, 2Elan Pharma, Stevenage, Hertfordshire, UK, 3Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK

PRS17	SELECTION OF UTILITY INSTRUMENTS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
	Lloyd A, Meguro M
	United BioSource Corporation, London, UK

PRS18	A PROCESS FOR DEVELOPING A PATIENT-CENTERED CONCEPTUAL FRAMEWORK FOR DYSPNEA AND RELATED FUNCTIONAL LIMITATIONS IN COPD
	Victorson DE1, Cella D1, Anton SF2, Hamilton A3, Langan JL4
	1Northwestern University Feinberg School of Medicine/Evanston Northwestern Healthcare, Evanston, IL, USA, 2Boehringer-Ingelheim, Ridgefield, CT, USA, 3Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada, 4Evanston Northwestern Healthcare, Evanston, IL, USA

STROKE

PST1	SEASONAL VARIATION OF TRANSIENT ISCHEMIC ATTACK (TIA) IN HUNGARY
	Kriszbacher I, Csoboth I, Boncz I, Bódis J
	University of Pécs, Pécs, Hungary

PST2	A CRITICAL REVIEW OF PUBLISHED ECONOMIC MODELLING STUDIES IN ISCHAEMIC STROKE
	Saragoussi D, Guilhaume C, Sapin C, François C
	H. Lundbeck A/S, Paris, France

PST3	STROKE SURVIVORS' CHANGE IN HEALTH RELATED QUALITY OF LIFE OVER TIME AS MEASURED BY THE STROKE IMPACT SCALE
	Wasserman J, Godwin KM, Ostwald SK, Cron S
	University of Texas-Houston School of Nursing, Houston, TX, USA

URINARY/KIDNEY

PUK1	EFFECT OF LAUGHTER THERAPY ON STRESS AND HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS
	Park H1, Kim S2, Heo E3, Yang D3
	1Pochon CHA University, Sungnam, Gyeonggi-Do, South Korea, 2Kyung Hee University, Seoul, South Korea, 3Bundang CHA Hospital, Sungnam, Gyeonggi-Do, South Korea

PUK2	COMPARING THE CLINICAL OUTCOMES FOLLOWING URINARY INCONTINENCE TREATMENT BY DIFFERENT TYPE OF SURGERY
	Oláh A1, Katona G1, Betlehem J1, Müller Á1, Sebestyén A2, Kriszbacher I1, Bódis J1, Boncz I1
	1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, Hungary

PUK3	REIMBURSEMENT INCENTIVE FOR PERITONEAL DIALYSIS MAY GENERATE BUDGET SAVINGS FOR ROMANIA
	Walker DR1, Bhattacharyya SK1, Capsa D2
	1Baxter Healthcare Corporation, McGaw Park, IL, USA, 2Fundeni Clinical Institute, Bucharest, Romania

PUK4	IN THE UK, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)
	Sondhi S1, Walker DR2
	1Baxter Healthcare, Newbury, Berks, UK, 2Baxter Healthcare Corporation, McGaw Park, IL, USA

PUK5	RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION
	Tolkushin AG, Kulikov A, Yagudina RI, Morozov A
	Moscow Medical Academy, Moscow, Russia

PUK6	RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION
	Tolkushin AG, Kulikov A, Yagudina RI, Morozov A
	Moscow Medical Academy, Moscow, Russia

PUK7	A COST-MINIMIZATION ANALYSIS OF OXYBUTYNIN (TRANSDERMAL DELIVERY SYSTEM) COMPARED TO TOLTERODINE (TABLETS) IN THE TREATMENT OF PATIENTS WITH URGE OR MIXED URINARY INCONTINENCE IN SWEDEN
	Sverre JM, Holm LB, Kristensen FKO
	PharmEcon, Asker, Akershus, Norway

PUK8	CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEY TRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND
	Kawalec P1, Szkultecka-Debek M2, Russel M2
	1Jagiellonian University, Krakow, Poland, 2Roche Poland, Warsaw, Poland

PUK9	HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSIS TREATMENT IN HUNGARY
	Gulacsi L1, Pentek M2, Becsi R1, Ecseki A1, Szabolcsi S2, Gyanyi M3, Brodszky V1, Szabo T3, Toth E2
	1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3BBraun Dialysis Centre of Kistarcsa, Kistarcsa, Hungary

PUK10	DIRECT COST OF URINARY INCONTINENCE OF ICELANDIC WOMEN, 16 YEARS AND OLDER IN THE YEAR 2004
	Hauksdottir R1, Geirsson G2, Baldursson FM1
	1University of Iceland, Reykjavik, Iceland, 2Landspitali-University Hospital, Reykjavik, Iceland

PUK11	THE COST OF END STAGE RENAL DISEASE IN GREECE
	Stafylas P1, Aletras V2
	1AHEPA University Hospital, Thessaloniki, Greece, 2University of Macedonia, Thessaloniki, Greece

PUK12	THE ECONOMIC BURDEN OF HAEMODIALYSIS IN GREECE DURING 2006
	Aletras V1, Stafylas P2
	1University of Macedonia, Thessaloniki, Greece, 2AHEPA University Hospital, Thessaloniki, Greece

PUK13	COST OF DIALYSIS IN A UK SETTING – A MULTICENTRE MICROCOSTING STUDY
	Baboolal K1, Spiewanowski P2, McEwan P2, Sondhi S3, Wilson K3, Wechowski JG2
	1University Hospital of Wales, Cardiff, Wales, UK, 2Cardiff Research Consortium, Cardiff, Wales, UK, 3Baxter Healthcare, Thetford, UK

PUK14	TIME SPENT ON ANAEMIA MANAGEMENT WITH ERYTHROPOIETIN STIMULATING AGENTS (ESA) IN HAEMODIALYSIS CENTRES: A CROSS-COUNTRIES PERSPECTIVE
	De Cock E1, Van Nooten F2, Sapède C3, Dale P4, Petrillo J5, Werner M6
	1United BioSource Corporation, Barcelona, Spain, 2United BioSource Corporation, Brussels, Belgium, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4United Biosource, London, England, UK, 5United BioSource Corporation, Bethesda, MD, USA, 6United BioSource Corporation, Seattle, WA, USA

PUK15	AN INTERNATIONAL ECONOMIC EVALUATION OF SEVELAMER HYDROCHLORIDE VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS NEW TO DIALYSIS
	Taylor MJ1, Chaplin S2, Elgazzar H3
	1University of York, York, UK, 2York Health Economics Consortium, York, North Yorkshire, UK, 3Genzyme Therapeutics, Oxford, UK

PUK16	GLOBAL ECONOMIC EVALUATIONS OF DIALYSIS TREATMENT MODALITIES
	Just PM1, Riella MC2, Tschosik EA3, Noe LL3, De Charro FT4, Bhattacharyya SK1
	1Baxter Healthcare Corporation, Renal Division, McGaw Park, IL, USA, 2Catholic University of Parana, Curitiba, Brazil, 3ICON Lifecycle Sciences Group, Highland Park, IL, USA, 4Erasmus University Rotterdam, Rotterdam, The Netherlands

PUK17	ENDOSCOPIC INJECTION VERSUS ANTIBIOTIC PROPHYLAXIS IN THE REDUCTION OF URINARY TRACT INFECTIONS IN PATIENTS WITH VESICOURETERAL REFLUX
	Elder JS1, Eaddy M2, Forsberg A3
	1Rainbow Babies and Children’s Hospital, Cleveland, OH, USA, 2Xcenda, Palm Harbor, FL, USA, 3Q-Med Scandinavia Inc, Princeton, NJ, USA

PUK18	INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY
	Boncz I1, Sebestyén A2, Pintér I1, Ágoston I1, Betlehem J1, Oláh A1, Gulácsi L3, Nagy J1
	1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Pécs, Hungary, 3Corvinus University of Budapest, Budapest, Hungary

PUK19	TREATMENT OUTCOMES AND MEDICAL CARE OF PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) RECEIVING BOTULINUM TOXIN A (BOTOX®) THERAPY
	Ehlken B1, Bremer J2, Burgdörfer H3, Domurath B4, Hampel C5, Kutzenberger J4, Seif C6, Sievert KD7, Wefer B6, Bär K8, Berger K1, Pannek J9
	1MERG - Medical Economics Research Group, Munich, Germany, 2Neurologisches Rehabilitationszentrum Greifswald GmbH, Greifswald, Germany, 3BG-Unfallkrankenhaus Hamburg, Hamburg, Germany, 4Werner-Wicker-Klinik, Bad Wildungen-Reinhardshausen, Germany, 5Johannes-Gutenberg-Universität, Mainz, Germany, 6Klinik für Urologie & Kinderurologie des Universitätsklinikums Schleswig-Holstein, Kiel, Germany, 7Universitätsklinikum Tübingen, Tübingen, Germany, 8Pharm-Allergan GmbH, Ettlingen, Germany, 9Schweizer Paraplegiker Vereinigung, Nottwil, Switzerland

PUK20	A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
	Kang HH, Bae JY, Park SY, Sohn HS
	Sook Myung women's University, Seoul, South Korea

PUK21	THE IMPACT OF ICODEXTRIN ON QUALITY OF LIFE IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS OVER TIME: A REGRESSION ANALYSIS
	Walker DR1, Paniagua R2, DuChane J3, Prieto I4, Divino J5, Blackburn JC6, Bhattacharyya SK3
	1Baxter Healthcare Corporation, McGaw Park, IL, USA, 2Unidad de Investigacion Medica en Enfermedades Nefrologicas, Mexico City, Mexico, 3Baxter Health Care, McGaw Park, IL, USA, 4Baxter Internacional, Mexico City, Mexico, 5Baxter Renal Division Intercontinental, Mexico City, Mexico, 6Baxter Export Corporation, Fort Lauderdale, FL, USA

PUK22	AN OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH A NEUROGENIC OVERACTIVE BLADDER TREATED WITH TOLTERODINE ER
	De Ridder D1, Ackaert K2, Dewilde L3, Everaert K4, Keppenne V5, Van Erps P6, Van Vliet P7, Vanderdonck F8, Van Campenhout H8
	1National MS Centre, Melsbroek, Belgium, 2St Elisabeth ziekenhuis, Turnhout, Belgium, 3Alg Ziekenhuis Stuyvenberg, Antwerpen, Belgium, 4UZ Gent, Gent, Belgium, 5CHU de Liège, Liège, Belgium, 6AZ Middelheim, Antwerpen, Belgium, 7AZ Jan Palfijn, Antwerpen, Belgium, 8Pfizer Belgium, Brussels, Belgium

PUK23	ILLNESS REPRESENTATIONS IN RENAL TRANSPLANT RECIPIENTS
	Valdés C, Moreno D, Ortega T, Ortega F
	Hospital Universitario Central de Asturias, Oviedo, Spain